Hypothesis

Intermittent dosing of the senolytic combination dasatinib + quercetin (D+Q) creates a transient, reversible stress window that preferentially eliminates epigenetically compromised somatic cells while allowing healthy cells to recover, mimicking the stringent selection pressure that maintains germline integrity across generations. Over successive cycles this selective pressure enriches the somatic cell pool for epigenetically youthful phenotypes, producing durable tissue rejuvenation without continuous drug exposure.

Mechanistic Rationale

1. Transient chromatin perturbation – A single low‑dose D+Q exposure induces reversible histone acetylation changes and a brief DNA‑damage response in young cells, which resolve within 24 h via SIRT6‑dependent repair and homologous recombination 2. Senescent cells, already burdened with persistent DNA damage and maladaptive SASP signaling, fail to repair and undergo apoptosis.
2. Mitochondrial ROS spike – Dasatinib inhibits Src family kinases, transiently elevating mitochondrial superoxide; quercetin blocks PI3K/Akt, reducing antioxidant capacity. Healthy cells activate Nrf2‑mediated antioxidant programs, whereas senescent cells, with compromised Nrf2 signaling, accumulate lethal oxidative damage 1.
3. Selection bottleneck analogy – In the germline, oocytes with high mitochondrial ROS or meiotic errors are eliminated at each reproductive bottleneck. Intermittent D+Q imposes a comparable bottleneck on somatic cells: each drug pulse removes the most damaged cells, and the recovery interval allows the surviving population to expand.
4. Epigenetic inheritance of youth – Surviving cells exhibit reduced heterochromatin loss and restored H3K9me3 patterns, as shown by the durable downregulation of SASP and upregulation of chondroanabolic genes after drug withdrawal [1]. Repeated bottlenecks thus shift the average epigenetic age of the tissue downward, measurable by DNA‑methylation clocks.

Testable Predictions

• In vivo: Aged mice receiving 3‑day D+Q pulses every 4 days for 8 weeks will show a greater reduction in p16^INK4a^‑positive senescent cells and a larger decrease in hippocampal epigenetic age than mice receiving continuous low‑dose D+Q or vehicle.
• Ex vivo: Single‑cell RNA‑seq of liver from treated mice will reveal a narrowed distribution of transcriptional variance and an increased proportion of cells expressing youthful markers (e.g., Alfp, Hnf4a) compared with controls.
• In vitro: Human fibroblasts subjected to repeated 48‑h D+Q exposures will display progressive senescence‑associated β‑galactosidase loss and a stepwise decline in epigenetic age measured by the Horvath clock, whereas a single exposure yields only transient changes.

Falsifiability

If intermittent D+Q fails to produce a significant, persistent reduction in senescent cell burden or epigenetic age relative to controls, or if young‑cell cytotoxicity accumulates over cycles, the hypothesis that germline‑like selection drives the observed benefits is refuted.

References

• Dasatinib and quercetin synergistically target senescent cells via complementary kinase and PI3K/Akt pathways 1.
• Intermittent dosing exploits differential chromatin remodeling in young versus senescent cells 2.